We are live on
!
Find out more
Pacer Advisors Portfolio holdings
AUM
$35.6B
1-Year Est. Return
18.19%
This Fund
S&P 500
This Quarter
Est. Return
-4.36%
1 Year Est. Return
+18.19%
3 Year Est. Return
+46.13%
5 Year Est. Return
+70.99%
10 Year Est. Return
+394.12%
AUM
$44.1B
AUM Growth
+$629M
(+1.4%)
Cap. Flow
+$2.39B
Cap. Flow
% of AUM
5.42%
Top 10 Holdings %
Top 10 Hldgs %
11.51%
Holding
3,945
New
199
Increased
895
Reduced
1,260
Closed
190
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Halliburton
HAL
|
+$500M |
| 2 |
Archer Daniels Midland
ADM
|
+$463M |
| 3 |
Hewlett Packard
HPE
|
+$425M |
| 4 |
Gen Digital
GEN
|
+$379M |
| 5 |
WCC
WESCO International
WCC
|
+$269M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vistra
VST
|
+$598M |
| 2 |
ExxonMobil
XOM
|
+$504M |
| 3 |
Chevron
CVX
|
+$443M |
| 4 |
Occidental Petroleum
OXY
|
+$439M |
| 5 |
Cummins
CMI
|
+$414M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Consumer Discretionary | 17.1% |
| 2 | Technology | 16.69% |
| 3 | Energy | 13.9% |
| 4 | Industrials | 11.2% |
| 5 | Healthcare | 9.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1276
Carvana
CVNA
$45.5B
| $40.3K | ﹤0.01% |
1,565
-1,685
| -52% | -$33.9K |
|
1277
Protolabs
PRLB
$1.85B
| $39.5K | ﹤0.01% |
1,278
+234
| +22% | +$7.42K |
|
1278
BridgeBio Pharma
BBIO
$16.6B
| $39.1K | ﹤0.01% |
1,545
+72
| +5% | +$1.97K |
|
1279
Biohaven
BHVN
$2.21B
| $38.6K | ﹤0.01% |
1,113
+376
| +51% | +$14.9K |
|
1280
Stratasys
SSYS
$699M
| $37.2K | ﹤0.01% |
4,433
+1,195
| +37% | +$11.4K |
|
1281
Amphastar Pharmaceuticals
AMPH
$843M
| $37.1K | ﹤0.01% |
927
+135
| +17% | +$5.59K |
|
1282
Cable One
CABO
$229M
| $35.4K | ﹤0.01% |
100
-569
| -85% | -$218K |
|
1283
CONMED
CNMD
$1.3B
| $34.8K | ﹤0.01% |
+502
| New | +$36.6K |
|
1284
Rapid7
RPD
$658M
| $34.7K | ﹤0.01% |
802
-186
| -19% | -$7.75K |
|
1285
TG Therapeutics
TGTX
$8.55B
| $34.1K | ﹤0.01% |
1,917
-625
| -25% | -$9.97K |
|
|
SWTX
1286
DELISTED
SpringWorks Therapeutics
SWTX
| $33.4K | ﹤0.01% |
887
+53
| +6% | +$2.23K |
|
1287
Iovance Biotherapeutics
IOVA
$2.23B
| $30.7K | ﹤0.01% |
3,831
+1,115
| +41% | +$11.9K |
|
1288
Ambarella
AMBA
$2.89B
| $30.2K | ﹤0.01% |
560
-104
| -16% | -$5.17K |
|
1289
Global E Online
GLBE
$6.4B
| $30K | ﹤0.01% |
826
-40
| -5% | -$1.29K |
|
1290
Calix
CALX
$2.32B
| $29.9K | ﹤0.01% |
843
-207
| -20% | -$6.66K |
|
1291
NetEase
NTES
$79.4B
| $29.6K | ﹤0.01% |
310
+13
| +4% | +$1.24K |
|
1292
DoubleVerify
DV
$1.7B
| $29.6K | ﹤0.01% |
1,520
+276
| +22% | +$6.67K |
|
1293
Ultragenyx Pharmaceutical
RARE
$2.67B
| $29.5K | ﹤0.01% |
718
-122
| -15% | -$5.21K |
|
1294
Dyne Therapeutics
DYN
$4.22B
| $29.2K | ﹤0.01% |
827
-773
| -48% | -$22.5K |
|
1295
Twist Bioscience
TWST
$5.35B
| $28.9K | ﹤0.01% |
586
-552
| -49% | -$22.5K |
|
1296
Crinetics Pharmaceuticals
CRNX
$8.88B
| $28.6K | ﹤0.01% |
638
-373
| -37% | -$17.2K |
|
1297
Acadia Pharmaceuticals
ACAD
$4.39B
| $28.2K | ﹤0.01% |
1,735
-87
| -5% | -$1.4K |
|
|
NUVL
1298
DELISTED
Nuvalent
NUVL
| $27.9K | ﹤0.01% |
368
-133
| -27% | -$9.46K |
|
1299
3D Systems Corp
DDD
$430M
| $27.4K | ﹤0.01% |
8,924
+2,662
| +43% | +$9.76K |
|
1300
Ardelyx
ARDX
$1.26B
| $27.1K | ﹤0.01% |
3,656
-1,253
| -26% | -$8.81K |
|
Similar funds
SAM
Pacer Advisors's Q2 2024 Portfolio in Review
As of Q2 2024, Pacer Advisors held 3,945 positions worth $44.1B, up 1.4% from $43.5B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Pacer Advisors deployed $2.39B of net new capital in Q2 2024, opening 199 new positions and adding to 895 existing holdings. Its largest new stake was Academy Sports + Outdoors: 3,268,629 shares worth $174M.
By sector, the portfolio is most concentrated in Consumer Discretionary at 17% of assets, down from 17% a quarter earlier, followed by Technology and Energy.
On the sell side, the largest reduction was Vistra, an estimated $598M trimmed.
- Pacer Advisors's largest Q2 2024 buy was Academy Sports + Outdoors: 3,268,629 shares worth $174M.
- Pacer Advisors added most to Halliburton in Q2 2024, an estimated $500M increase.
- Pacer Advisors's biggest Q2 2024 reduction was Vistra, cutting an estimated $598M.
- Pacer Advisors fully exited American Eagle Outfitters in Q2 2024, selling an estimated $218M.
- Pacer Advisors's ten largest holdings make up 12% of its $44.1B portfolio in Q2 2024.
- Pacer Advisors opened 199 new positions and closed 190 in Q2 2024.
- Pacer Advisors's portfolio value rose 1.4% quarter-over-quarter to $44.1B.
Based on Pacer Advisors's 13F filing for Q2 2024, filed 13 Aug 2024.